Evidence Hub

Clinical characteristics, risk factors and prognosis of Klebsiella pneumoniae infection in patients with different states of immune function: a retrospective study

Wang X, Xu C, Qin C, Liu J, Kong X, Zhu Z, Zhang C, Xu W et al.

Frontiers in cellular and infection microbiology, 2025

228 participants · 2 citations

Abstract

Background: The aim of our study was to investigate the epidemiology and risk factors of Klebsiella pneumoniae (KP) infection in immunocompromised patients and to compare the differences in prognosis among patients with different immune states in the extended-spectrum beta-lactamase KP (ESBL-KP), the carbapenem-resistant KP (CRKP), and the non-multidrug-resistant KP (non-MDR-KP) groups.

Methods: We conducted a retrospective study in immunocompromised and immunocompetent patients with KP infections who were admitted to Chaohu Hospital of Anhui Medical University from January 2023 to December 2023. We compared demographics, clinical characteristics, treatments, and outcomes across these groups and examined the impact of ESBL-KP, CRKP and non-MDR-KP on cumulative survival rates in populations with different immune states by plotting Kaplan-Meier curves.

Results: Our study included 228 immunocompromised patients and 200 immunocompetent patients. Compared to the immunocompetent group, immunocompromised patients were more likely to have a history of surgery and to use hormone frequently. They tended to rely more on medical devices, including urinary catheters, nasogastric catheters, arterial catheters, venous catheters, mechanical ventilation and endoscopy. Immunocompromised patients had a poorer recovery and were rehospitalized more often than those in immunocompetent patients. In the multivariable analysis, age-adjusted Charlson comorbidity index (aCCI) (OR: 1.292, 95%CI:…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 228 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free